Stem cell data showing durable frailty gains earn Longeveron a $1 million XPRIZE Healthspan milestone award.
Part of a ten-part series profiling each of the $101 million XPRIZE Healthspan competition’s Milestone 2 Awardees. Across the series, Longevity.Technology examines the science behind each team’s approach, the trial data supporting it and what stands between them and the competition’s final phase.
Out of more than 600 teams from 58 countries that entered the XPRIZE Healthspan competition, only ten made it through to Milestone 2. Longeveron, a Miami-based regenerative medicine company, is one of them, and the reason lies in a walking test that most people would barely think twice about.
The XPRIZE Healthspan competition is a seven-year, $101 million global challenge built around a simple premise: develop and test a therapy that can restore muscle, cognition and immune function lost to ageing by at least ten years, ideally twenty, and do it within a year or less of treatment. It is one of the most ambitious prizes in the longevity field, and Longeveron’s path to the finals began with a modest but telling clinical measure, the six-minute walk distance.
A cell therapy built from young donor tissue
Longeveron’s lead candidate, laromestrocel, is an allogeneic mesenchymal stem cell (MSC) therapy derived from the bone marrow of young, healthy adult donors. Unlike therapies that rely on a patient’s own cells, an allogeneic approach uses donor-derived cells manufactured at scale, which is part of what makes it a plausible candidate for the kind of broad, one-time intervention XPRIZE is looking for. The cells are believed to work through several overlapping mechanisms, including anti-inflammatory, pro-vascular and pro-regenerative effects, rather than a single, narrow pathway.
It was published clinical trial data demonstrating that laromestrocel increased six-minute walk distance in patients with aging-related frailty that secured Longeveron’s place among the Milestone 2 Awardees. The six-minute walk test is a standard measure of functional capacity and endurance, and meaningful improvement on it in an older, frail population is a reasonably direct proxy for the kind of functional restoration XPRIZE is designed to reward.
From bone marrow to boardroom: a pipeline built on one platform
What distinguishes Longeveron’s broader story is the breadth of what a single cell platform is being asked to do. The company describes its approach as a “pipeline-in-a-product” strategy, testing laromestrocel across four distinct indications: hypoplastic left heart syndrome, a rare pediatric heart condition, Alzheimer’s disease, pediatric dilated cardiomyopathy and aging-related frailty. That range has already attracted five separate FDA designations, including Regenerative Medicine Advanced Therapy and Fast Track status for the Alzheimer’s programme as well as Orphan Drug, Fast Track, and Rare Pediatric Disease designations for the heart syndrome programme.
Dr Joshua Hare, Longeveron’s co-founder and chief science officer, pointed to a portfolio of 52 issued patents worldwide that support the platform, alongside positive initial results from five clinical trials across the three indications. For a clinical-stage biotech, that combination of regulatory momentum and intellectual property depth is what makes a multi-indication strategy credible rather than diffuse [1].
What Milestone 2 means
The $1 million award is not the finish line. It funds Longeveron’s participation in the competition’s final phase, where the top-performing teams will run coordinated clinical trials through 2029, competing for a grand prize of up to $81 million. XPRIZE’s evaluators assessed applicants on scientific merit and clinical readiness, screening for the therapies best positioned to demonstrate real restoration of function in adults aged 50 to 90 who are free of major disease, not merely a slowing of decline.
CEO Stephen Willard described the milestone as the start of the competition’s next chapter, one in which Longeveron will continue advancing a therapy the company believes can meaningfully extend healthy life for patients and their families [1].
Why it matters for longevity
Frailty is one of the clearest and most measurable markers of biological aging, and it is also one of the most consequential: loss of muscle function and mobility drives falls, hospitalizations and loss of independence in older adults far more than any single disease diagnosis.
A therapy that can durably restore walking capacity in frail, older patients is a direct assault on one of aging’s most disabling downstream effects. Longeveron’s advancement in a competition explicitly built around restoring lost function, rather than simply extending years lived, reflects where a meaningful share of longevity science is heading: toward interventions judged not by lifespan alone, but by how much of that life remains genuinely functional.
